万基遗传美股招股说明书(2026-03-04版)

$ 200,000,000COMMON STOCK We may from time to time issue up to $200,000,000 aggregate principal amount of common stock, preferred stock, depositary shares,debt securities and/or warrants. This prospectus provides a general description of the securities we may offer. Each time we offersecurities, we will provide the specific terms of the securities offered in a supplement to this prospectus. We may also authorize one ormore free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related Our securities may be sold directly by us to you, through agents designated from time to time or to or through underwriters or dealers.For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus andin the applicable prospectus supplement. If any underwriters or agents are involved in the sale of our securities with respect to whichthis prospectus is being delivered, the names of such underwriters or agents and any applicable fees, commissions or discounts and Our common stock is listed on The Nasdaq Global Select Market under the symbol “MYGN.” On February 19, 2026, the last reportedsale price of our common stock on The Nasdaq Global Select Market was $4.38 per share. Prospective purchasers of common stock Investing in our securities involves risks. See “Risk Factors” included in any accompanying prospectus supplement or anyrelated free writing prospectus and in the documents incorporated by reference in this prospectus for a discussion of the Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. This prospectus may not be used to consummate sales of securities unless it is accompanied by a prospectus supplement. The date of this prospectus is March 4, 2026. ABOUT THIS PROSPECTUSPROSPECTUS SUMMARYRISK FACTORSSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSUSE OF PROCEEDSPLAN OF DISTRIBUTIONDESCRIPTION OF COMMON STOCKDESCRIPTION OF PREFERRED STOCKDESCRIPTION OF DEPOSITARY SHARESDESCRIPTION OF DEBT SECURITIESDESCRIPTION OF WARRANTSLEGAL MATTERSEXPERTSWHERE YOU CAN FIND MORE INFORMATIONINCORPORATION OF DOCUMENTS BY REFERENCE ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a“shelf” registration process. Under this shelf process, we may sell any combination of the securities described in this prospectus in oneor more offerings up to a total dollar amount of $200,000,000. We have provided to you in this prospectus a general description of thesecurities we may offer. Each time we sell securities, we will provide a prospectus supplement to this prospectus that will contain This prospectus does not contain all of the information included in the registration statement. For a more complete understanding ofthe offering of the securities, you should refer to the registration statement, including its exhibits. The prospectus supplement and anyrelated free writing prospectus may also add, update or change information contained in this prospectus. You should read both this This prospectus may not be used to consummate sales of securities, unless it is accompanied by a prospectus supplement coveringthose securities. To the extent there are inconsistencies between any prospectus supplement, any related free writing prospectus, this You should rely only on information contained in, or incorporated by reference into, this prospectus and any prospectus supplementand any related free writing prospectus. We have not authorized anyone to provide you with information different from that containedin this prospectus or incorporated by reference in this prospectus. We are not making offers to sell the securities in any jurisdiction in The information in this prospectus is accurate as of the date on the front cover. You should not assume that the information contained “We,” “us,” “our,” “Myriad” and the “Company” as used in this prospectus refer to Myriad Genetics, Inc., a Delaware corporation, andits subsidiaries. PROSPECTUS SUMMARY The following is a summary of what we believe to be the most important aspects of our business and the offering of our securitiesunder this prospectus. We urge you to read this entire prospectus, including the more detailed consolidated financial statements, notesto the consolidated financial statements and other information incorporated by reference from our other filings with the SEC orincluded in any applicable prospectus supplementand any related free writing prospectus. Investing in our securities involves risks.Therefore, carefully consider the risk factors set forth in any prospectus supplements, any related free writing prospectus and in ourmost recent annual and quarterly fi